community download

What happens to Biosimilars being developed under 505b(2)?

Dave Nitesh of Biocon joined us for World Biosimilar Congress USA 2016 to discuss what happens to biosimilars being developed under 505b (2) .
 
Download this presentation to understand more about:
  • Key features of 505b (2)
  • Key features of 351k (1, 2)
  • Products approved under 505b (2)
  • Path ahead for products under development

and more !

 

Get your copy here


 
If you're interested in learning more about biosimilars being developed, join us for World Biosimilar Congress USA 2017 , held May 23-24 in San Diego, CA . This event is co-located with Americas Antibody Congress and Cell Culture World Congress USA. 

Some quick details

Email Address:*
First name:*
Last name:*
Job Title:*
Company:*
Industry:
Country:*

Remember my details Information

Information
Remember my details
We place a 'cookie' on your computer so next time you visit us you don't need to fill in all these details


Privacy statement »
Manage your email preferences »
 

You will be emailed the document as an attachment (430Kb in size)